The 56 Point TA; Charts With an Attitude Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug R who wrote (8029)	11/20/1997 7:30:00 PM
From: majormember	Read Replies (1) of 79438

Doug R. Simple stuff on SNRS. First go to these posts: talk.techstocks.com and talk.techstocks.com Go to home page: sunrise-tech.com Request an invester kit which will come with a full detailed Red Chip Review. Forbes Nov. 3rd issue has full page on SNRS (in the special sight ad section, pg.12) For the more resourceful I highly recommend: 1. Print complete charts for VISX, BEAM & SNRS. These are the 3 main players in the laser/vision field. VISX & BEAM have had their day with the excimer laser. LASIK is invasive and will quickly become obsolete when a non-invasive procedure appears. 2. Look in archives of wall st. journal (don't think there is any charge unless you order a story). Find the dates on the charts where MAJER price moves occured, and find the correlated story (a few days before usually). You can also join the American Opthalmologic site which will link you to other sites regarding all aspects of vision laser surgery. 3. Speak to a KNOWLEDGEABLE M.D. who performs KRT technique with the VISX or Summit system. He/She will probably be aware of this technology, and are probably investers if they know the procedure. You should all return as experts, with the quiet assurance that the "Street" reacts VERY WELL to companies that come out with this type of technology, even if it doesn't do well AFTER FDA approval. By the time OF FDA approval the "other" stocks were above $35. At this point, you should hopefully reach the same conclusion that I have. FDA approval is almost certain with the CEO and current Mgmt. team in place. At $4 3/4 a share and financing in place to complete clinical reviews, as well as FDA/Congress new "Fast Track" process, there is no downside now that we are cleared for Phase III trails, and there will be pleanty of places to exit at many higher price points. Best regards, Skane

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next